Receptor, Fibroblast Growth Factor, Type 2
"Receptor, Fibroblast Growth Factor, Type 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fibroblast growth factor receptor which contains three extracellular IMMUNOGLOBULIN I-SET DOMAINS and is expressed as two isoforms. One receptor isoform is expressed in the MESENCHYME and is activated by FIBROBLAST GROWTH FACTOR 2. A second isoform is expressed mainly by EPITHELIAL CELLS and is activated by FIBROBLAST GROWTH FACTOR 7 and FIBROBLAST GROWTH FACTOR 10. Mutation of the gene for fibroblast growth factor receptor 2 can result in craniosynostotic syndromes (e.g., APERT SYNDROME; and CROUZON SYNDROME).
| Descriptor ID |
D051497
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.178 D12.776.543.750.630.441 D12.776.543.750.750.400.370.750
|
| Concept/Terms |
Receptor, Fibroblast Growth Factor, Type 2- Receptor, Fibroblast Growth Factor, Type 2
- BEK Fibroblast Growth Factor Receptor
- BEK Protein Tyrosine Kinase
- Bek Fgf Receptor Kinase
- Fibroblast Growth Factor Receptor 2
- Bek-Related Fibroblast Growth Factor-Receptor-1
- Bek Related Fibroblast Growth Factor Receptor 1
- Fibroblast Growth Factor Receptors 2
- FGFR2 Protein
- CD332 Antigen
- Antigen, CD332
- BEK Fibroblast Growth Factor Receptor Kinase
|
Below are MeSH descriptors whose meaning is more general than "Receptor, Fibroblast Growth Factor, Type 2".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptor, Fibroblast Growth Factor, Type 2 [D08.811.913.696.620.682.725.400.178]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- Receptor, Fibroblast Growth Factor, Type 2 [D12.776.543.750.630.441]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptors, Fibroblast Growth Factor [D12.776.543.750.750.400.370]
- Receptor, Fibroblast Growth Factor, Type 2 [D12.776.543.750.750.400.370.750]
Below are MeSH descriptors whose meaning is more specific than "Receptor, Fibroblast Growth Factor, Type 2".
This graph shows the total number of publications written about "Receptor, Fibroblast Growth Factor, Type 2" by people in this website by year, and whether "Receptor, Fibroblast Growth Factor, Type 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, Fibroblast Growth Factor, Type 2" by people in Profiles.
-
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA. Cell Genom. 2025 Dec 10; 5(12):100987.
-
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. ESMO Open. 2024 Jun; 9(6):103488.
-
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial. Future Oncol. 2020 Oct; 16(30):2375-2384.
-
Complex Compound Inheritance of Lethal Lung Developmental Disorders Due to Disruption of the TBX-FGF Pathway. Am J Hum Genet. 2019 02 07; 104(2):213-228.
-
A genotype-specific surgical approach for patients with Pfeiffer syndrome due to W290C pathogenic variant in FGFR2 is associated with improved developmental outcomes and reduced mortality. Genet Med. 2019 02; 21(2):471-476.
-
Minor Suture Fusion in Syndromic Craniosynostosis. Plast Reconstr Surg. 2017 Sep; 140(3):434e-445e.
-
Paracrine signaling in mammary gland development: what can we learn about intratumoral heterogeneity? Breast Cancer Res. 2014 Jan 29; 16(1):202.
-
Competition between Grb2 and Plc?1 for FGFR2 regulates basal phospholipase activity and invasion. Nat Struct Mol Biol. 2014 Feb; 21(2):180-8.
-
Fibroblast growth factor receptor two (FGFR2) regulates uterine epithelial integrity and fertility in mice. Biol Reprod. 2014 Jan; 90(1):7.
-
Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May; 71(5):1315-23.